



8EHQ-94-12943
INIT 83/29/94

DuPont Central Research
and Development
Haskell Laboratory for Toxicology
and Industrial Medicine
P.O. Box 50, Elkton Road
Newark, DE 19714-0050
Fax: (302) 366-5207



DuPont Central Research
and Development

March 25, 1994

(A)

8EHQ-0394-12943

EXPRESS MAIL - RETURN RECEIPT REQUESTED
CONTAINS NO CONFIDENTIAL BUSINESS INFORMATION

Contains No CBI

OFFICE OF POLLUTION
PREVENTION AND TOXICS
94 MAR 29 AM 8:19

Document Processing Center (TS-790)
Attention: 8(e) Coordinator
Office of Pollution Prevention and Toxics
U. S. Environmental Protection Agency
401 M Street SW
Washington, D.C. 20460



88940000185

Dear Coordinator:

This letter is to inform you of certain effects recently noted in our review of two, pre-1977 studies on:

Ethanesulfonyl fluoride, 1,1,2,2-tetrafluoro-2-[1,2,2-trifluoro-1-(trifluoromethyl)-2-[(trifluoroethenyl)oxy]ethoxy]- (CAS No. 16090-14-5)

In an acute dermal toxicity study with rabbits, no deaths occurred at application rates from 670 mg/kg up to 17,000 mg/kg, the highest level tested. However, rabbits exhibited lethargy, cyanosis, closed eyes, pupillary constriction, and incoordination on the day of exposure and dose-related hindquarter stiffness which persisted from the second to the ninth day post exposure.

In an acute inhalation study in rats, the four-hour approximate lethal concentration was 12,600 ppm; terminal convulsions were seen in rats from this group prior to death. Deaths in this group were due to pulmonary edema/hemorrhage. In rats exposed to sublethal concentrations (i.e., 750-6500 ppm), incoordination and gasping were noted. Rats killed 14 days after exposure to 12,600 ppm had significantly increased liver weights.


Based on EPA guidance (1991) for reporting under TSCA Section 8(e), these results would appear to be reportable.

Sincerely,

Charles F. Reinhardt

Charles F. Reinhardt, M.D.
Director

CFR/RV:dj
Phone: (302) 366-5285





UNITED STATES ENVIRONMENTAL PROTECTION AGENCY
WASHINGTON, D.C. 20460

Dr. Charles F. Reinhardt, Director
Du Pont Central Research and Development
Haskell Laboratory for Toxicology and Industrial Medicine
P.O. Box 50, Elkton Road
Newark, Delaware 19714-0050

OFFICE OF
PREVENTION, PESTICIDES AND
TOXIC SUBSTANCES

DEC 08 1994

EPA acknowledges the receipt of information submitted by your organization under Section 8(e) of the Toxic Substances Control Act (TSCA). For your reference, copies of the first page(s) of your submission(s) are enclosed and display the TSCA §8(e) Document Control Number (e.g., 8EHQ-00-0000) assigned by EPA to your submission(s). Please cite the assigned 8(e) number when submitting follow-up or supplemental information and refer to the reverse side of this page for "EPA Information Requests".

All TSCA 8(e) submissions are placed in the public files unless confidentiality is claimed according to the procedures outlined in Part X of EPA's TSCA §8(e) policy statement (43 FR 11110, March 16, 1978). Confidential submissions received pursuant to the TSCA §8(e) Compliance Audit Program (CAP) should already contain information supporting confidentiality claims. This information is required and should be submitted if not done so previously. To substantiate claims, submit responses to the questions in the enclosure "Support Information for Confidentiality Claims". This same enclosure is used to support confidentiality claims for non-CAP submissions.

Please address any further correspondence with the Agency related to this TSCA 8(e) submission to:

Document Processing Center (7407)
Attn: TSCA Section 8(e) Coordinator
Office of Pollution Prevention and Toxics
U.S. Environmental Protection Agency
Washington, D.C. 20460-0001

EPA looks forward to continued cooperation with your organization in its ongoing efforts to evaluate and manage potential risks posed by chemicals to health and the environment.

Sincerely,

Terry R. O'Bryan

Terry R. O'Bryan
Risk Analysis Branch

Enclosure

12943 A



Recycled/Recyclables
Printed with Soy-based ink on paper that
contains at least 10% recycled fiber

Triage of 8(e) Submissions

Date sent to triage: JAN 17 1995

NON-CAP

CAP

Submission number: 12943A

TSCA Inventory:

Y

N

D

Study type (circle appropriate):

Group 1 - Dick Clements (1 copy total)

~~BOO~~

~~AQUATO~~

Group 2 - Ernie Falke (1 copy total)

ATOX

SBTOX

SEN

w/NEUR

Group 3 - Elizabeth Margosches (1 copy each)

STOX

CTOX

EPI

RTOX

GTOX

STOX/ONCO

CTOX/ONCO

IMMUNO

CYTO

NEUR

Other (FATE, EXPO, MET, etc.): _____

Notes:

THIS IS THE ORIGINAL 8(e) SUBMISSION; PLEASE REFILE AFTER TRIAGE DATABASE ENTRY

For Contractor Use Only

entire document: 0 2 pages 1 pages 1

Notes:

Contractor reviewer: FOR Date: 11/17/94

CECATS/TRIAGE TRACKING DBASE ENTRY FORM

CECATS DATA: Submission # 8EHO 0394-12943 SEQ. A

TYPE: INT. SUPP FLWP
 SUBMITTER NAME: Dupont Central Research and Development

INFORMATION REQUESTED: FLY P. DATE:
 0501 NO INFO REQUESTED
 0502 INFO REQUESTED (TECH)
 0503 INFO REQUESTED (VOL. ACTIONS)
 0504 INFO REQUESTED (REPORTING RATIONAL P.)
 DISPOSITION:
0505 REFER TO CHEMICAL SCREENING
 0578 CAP NOTICE

VOLUNTARY ACTIONS:
 0401 NO ACTION REQUIRED
 0402 STUDIES PLANNED (MINI HWAY)
 0403 NOTIFICATION (H WORK) (M CHANGES)
 0404 LABEL/MSDS (CHANGE)
 0405 PROCESS/AND/ING. (CHANGE)
 0406 APPAUSE DISCONTINUED
 0407 PRODUCTION DISCONTINUED
 0408 CONFIDENTIAL

SUB. DATE: 03/25/94 OTS DATE: 03/29/94 CSRAD DATE: 05/10/94
 CASE: 16090-14-5

CHEMICAL NAME: _____

INFORMATION TYPE:	P.F.C.	INFORMATION TYPE:	P.F.C.	INFORMATION TYPE:	P.F.C.
ONCO (HUMAN)	01 02 04	EPICLIN	01 02 04	IMMUNO (ANIMAL)	01 02 04
ONCO (ANIMAL)	01 02 04	HUMAN EXPOS (PROD CONTAM)	01 02 04	IMMUNO (HUMAN)	01 02 04
CELL TRANS (IN VITRO)	01 02 04	HUMAN EXPOS (ACCIDENTAL)	01 02 04	CHEM/PHYS PROP	01 01 04
MUTA (IN VITRO)	01 02 04	HUMAN EXPOS (MONITORING)	01 02 04	CLASTO (IN VITRO)	01 02 04
MUTA (IN VIVO)	01 02 04	ECO/AQUA TOX	01 02 04	CLASTO (ANIMAL)	01 02 04
REPRO/TERATO (HUMAN)	01 02 04	ENV. OCCUR/REL/FATE	01 02 04	DNA DAMAGE/PAIR	01 02 04
REPRO/TERATO (ANIMAL)	01 02 04	EMER INCI OF ENV CONTAM	01 02 04	PRODUCE/PROC	01 02 04
NEURO (HUMAN)	01 02 04	RESPONSE REBEST DELAY	01 02 04	MSDS	01 02 04
NEURO (ANIMAL)	01 02 04	PROD/COMP/CHEM ID	01 02 04	OTHER	01 02 04
ACUTE TOX. (HUMAN)	01 02 04	REPORTING RATIONALE	01 02 04		
CHIR. TOX. (HUMAN)	01 02 04	CONFIDENTIAL	01 02 04		
ACUTE TOX. (ANIMAL)	01 02 04	ALLERG (HUMAN)	01 02 04		
SUB ACUTE TOX (ANIMAL)	01 02 04	ALLERG (ANIMAL)	01 02 04		
SUB CHRONIC TOX (ANIMAL)	01 02 04	METAB/PHARMACO (ANIMAL)	01 02 04		
CHRONIC TOX (ANIMAL)	01 02 04	METAB/PHARMACO (HUMAN)	01 02 04		

TRIAGE DATA: NON-CBI INVENTORY
 YES
 NO
 IN NAME: _____

ONGOING REVIEW:
 YES (DROP/REFER) _____
 NO (CONTINUE) _____
 REFER _____

SPECIES: RBT
RAT

TOXICOLOGICAL CONCERN:
 LOW
 MED
 HIGH

USE: _____
 PRODUCTION: _____

UNCLASSIFIED Non-CBI

-CPSS- 0609951336

0 0 0 0 0 0 0 0 0 0 0

> <ID NUMBER>

8(E)-12943A

> <TOX CONCERN>

L

> <COMMENT>

ACUTE DERMAL TOXICITY IN RABBITS IS LOW CONCERN. ANIMALS WERE ADMINISTERED DOSES IN THE RANGE OF 670 - 17000 MG/KG WITH NO MORTALITY. CLINICAL SIGNS INCLUDED LETHARGY, CYANOSIS, CLOSED EYES, PUPILLARY CONSTRICTION, HIND- QUARTER STIFFNESS AND INCOORDINATION. ACUTE INHALATION TOXICITY IN RATS IS LOW CONCERN. ANIMALS WERE EXPOSED TO CONCENTRATIONS RANGING FROM 750 - 12600 PPM FOR 4 HOURS. MORTALITY OCCURRED AT 12600 PPM. ANIMALS THAT DIED EXHIBITED TERMINAL CONVULSIONS. CLINICAL SIGNS INCLUDED INCOORDINATION AND GASPING. PATHOLOGY OF SURVIVORS INCLUDED INCREASED LIVER WEIGHT. PATHOLOGY OF THE DECEDENTS REVEALED PULMONARY EDEMA/HEMORRHAGE.

\$\$\$\$